Markets

Insider Trading

Hedge Funds

Retirement

Opinion

10 Best Strong Buy Healthcare Stocks to Buy Now

Page 1 of 9

In this article, we will look at the 10 Best Strong Buy Healthcare Stocks to Buy Now.

On July 21, Jared Holz, Mizuho health care sector strategist, appeared on CNBC’s ‘The Exchange’ to talk about whether any opportunity plays exist within the healthcare sector, and what pains the sector is facing.

He stated that he is certainly frustrated about the current dynamics in healthcare, admitting that it would be great to cover a sector that outperforms the market once in a while.

The strategist said that when one looks back at healthcare versus the market in the past decade, and even more, the only years the sector has outperformed are when the market was down, and that isn’t a great setup either. A cascading effect of issues exists in large-cap pharma, which Holz considers a significant factor affecting the industry’s performance.

READ ALSO: 11 Best Shipping and Container Stocks to Invest in Now and 11 Best Affordable Stocks Under $5 to Invest in.

He further told CNBC that this is the worst the healthcare sector has ever traded, and nothing even comes close to this much pressure across the board if we go back a couple of decades. Holz named pharma and managed care as the biggest culprits, stating that they are carrying the most weight from a market-cap standpoint.

With these trends in view, let’s look at the best strong buy healthcare stocks to buy now.

A healthcare provider holding an MRI scan of a patient with a traumatic brain injury.

Our Methodology

We used Finviz and Tipranks to make a list of strong buy healthcare stocks and then selected the top 10 with consensus Strong Buy ratings and the highest number of hedge fund holders as of Q1 2025. We sourced the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund holders.

Note: All data was sourced on July 23.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

10 Best Strong Buy Healthcare Stocks to Buy Now

10. BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Number of Hedge Fund Holders: 59

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best strong buy healthcare stocks to buy now. On July 14, Leerink Partners analyst Mani Foroohar maintained a Buy rating on BridgeBio Pharma, Inc. (NASDAQ:BBIO) and set a price target of $56.00.

The analyst based the rating on the company’s promising future prospects, stating that it is poised to expand its portfolio beyond the launch of Attruby in ATTR-CM, with three Phase 3 readouts anticipated in the next nine months.

The analyst sees this diversification as an optimistic development as it reduces the company’s reliance on a single asset, potentially bolstering its market position.

Foroohar also identified the BBP-418 program in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) as a notable opportunity for BridgeBio Pharma, Inc. (NASDAQ:BBIO), as it is a high-margin asset that focuses on a rare disease with considerable unmet needs.

This offers BridgeBio Pharma, Inc. (NASDAQ:BBIO) pricing flexibility and paves the way to accelerated approval, according to the firm.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a commercial-stage biopharmaceutical company that discovers, creates, tests, and delivers transformative medicines to treat patients suffering from genetic diseases and cancers.

9. DexCom, Inc. (NASDAQ:DXCM)

Number of Hedge Fund Holders: 60

DexCom, Inc. (NASDAQ:DXCM) is one of the best strong buy healthcare stocks to buy now. On July 16, Mizuho analyst Anthony Petrone raised the firm’s price target on DexCom, Inc. (NASDAQ:DXCM) to $100 from $95 while keeping an Outperform rating on the shares.

The rating update came with the firm adjusting price targets in the medical devices and diagnostics sector ahead of Q2 2025 earnings. DexCom, Inc. (NASDAQ:DXCM) is set to report its Q2 results on July 30.

DexCom, Inc. (NASDAQ:DXCM) is a medical device company that manufactures continuous glucose monitoring (CGM) systems to allow real-time health management control. Specializing in diabetes care technology, the company helps improve and simplify diabetes management worldwide.

It offers various medical devices and products, including Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE.

Page 1 of 9

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!